Esperion falls after quarterly results miss estimates

Esperion Therapeutics

10/03/2026 14:42

** Shares of drug developer Esperion Therapeutics ESPR.O fall 4.61% to $2.90

** Co posts Q4 adjusted profit of 22 cents per share, compared to analysts' estimate of 24 cents per share, according to data compiled by LSEG

** Posts Q4 revenue of $168.4 million, missing analysts' estimate of $174.5 million

** ESPR shares down 22% YTD after having risen over 68% in 2025

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))